On Tuesday, Jan. 8, I will likely see
, which is presenting for the first time since the separation from Abbott. At
, investors should focus on R&D plans for the future, following major clinical failures for oral Remodulin (pulmonary arterial hypertension) and solanezumab (Alzheimer's disease), respectively. In both cases, I would be inclined to view management recalcitrance as a negative.
By Wednesday, Jan. 9, exhaustion sets in and elbowing through crowded hallways to reach even more crowded breakout rooms becomes a chore. Nonetheless, there are a host of interesting presentations. I'll likely listen in on
(NKTR - Get Report)
. I know Idenix and Sarepta well, so my attendance will be more to check in on each company's progress. I doubt either company will say anything dramatically new or different from what investors have heard already.
I don't know Nektar or Amicus well, but both stocks performed miserably in late 2012. Good, long investment ideas often emerge from the ashes of defeat. Finally, I want to learn more about Pharmacyclics. It's sustained stock outperformance and mind-boggling $4 billion market capitalization has caught my skeptical eye. (Of course, I also missed the company's multi-year gains. D'oh!)
Those interested in weight-loss drugs should also definitely pay attention to
(ARNA - Get Report)
presentation on Wednesday. The company has finally received DEA scheduling and is gearing up for the launch of Belviq. I'm excited the
commercial game is finally afoot
Thursday, Jan. 10 -- the closing day of the JPM conference -- will probably remain mostly unscheduled so I can see companies that strike my fancy at the last minute. I do want to sit in on the
breakout. The company sells Testim, a testosterone replacement gel, and Xiaflex, a collagenase enzyme for a rare disease known as Dupuytren's contracture. Auxilium also recently filed a supplemental Biologics License Application (sBLA) for Xiaflex as a treatment for Peyronie's disease. With a FDA approval decision date in early September, it's never too early to get up to speed.
Now, for my big news: Although I have thoroughly enjoyed my year-long sabbatical as a journalist, this will be my last column for
. Effective today, I return to the buyside as a partner in a new healthcare hedge fund.
Before we part ways, I want to thank everyone who took the time to read my columns over the past year. Even when we disagreed, your insights were frequently thought provoking and your insults uproariously entertaining. Most of all, I want to thank my editor and friend Adam Feuerstein, who encouraged me to start writing as a way to share my views on this complex and ever-changing sector while deciding on the next steps in my career.
One more point on Feuerstein. Both personally and professionally, I assure you that his detractors couldn't be more wrong. We don't always share the same view and he definitely thinks I'm an overly finicky wordsmith, but never have I met a more passionate and principled advocate for the biotech sector.
and biotech investors are extremely lucky to have his thoughtful viewpoint, whether right or wrong. I'm fortunate to call him a friend.
Let me leave you with a favorite quote of mine from Winston Churchill that I often think about when stressed about inexplicable stock movements, investors who smugly act as though they "know something," or fears of waning interest in the biotech sector. Churchill's statement has both nothing and everything to do with life as a fundamentals-oriented healthcare investor, and is a perfect reminder of what long-term investors should focus on.
"The truth is incontrovertible, malice may attack it, ignorance may deride it, but in the end; there it is."
Sadeghi has no positions in stocks mentioned.